Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“I find MedCity News a great resource for taking the pulse of the market and sourcing potential investment opportunities.”

Bernie Rudnick, Angel investor and advisor, CapGenic Advisors, LLC


Sign up for our daily newsletter


Avastin shows promise against glioblastoma, Roche says

August 10, 2012 1:22 am by | 0 Comments

brain

Swiss drugmaker Roche Holding AG said a new study of cancer drug Avastin showed it significantly extended life expectancy of people with an aggressive form of brain cancer.

The Phase III AVAglio study met one of its main targets of improving progression-free survival in people with glioblastoma, Roche, the world's largest maker of cancer drugs, said in a statement on Friday.

"This study showed that people with glioblastoma, a particularly devastating and aggressive cancer without many treatment options, lived significantly longer without their disease worsening when Avastin was added to radiation and temozolomide chemotherapy," Roche said.

(Reporting by Andrew Thompson)

[Photo courtesy of Flickr user IsaacMao] Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
0 comments